Hyperparathyroidism Market 2024-2028
The hyperparathyroidism market is forecasted to grow by USD 486.7 mn during 2023-2028, accelerating at a CAGR of 7.1% during the forecast period. The report on the hyperparathyroidism market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in thyroid treatment awareness programs, growing focus on emerging economies, and increasing drug discovery.
Technavio's hyperparathyroidism market is segmented as below:
- By Disease Type
- Secondary hyperparathyroidism
- Primary hyperparathyroidism
- Tertiary hyperparathyroidism
- By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing inorganic growth strategies among vendors as one of the prime reasons driving the hyperparathyroidism market growth during the next few years. Also, growing penetration of e-commerce for drug retail and rising clinical trials for hyperparathyroidism treatment will lead to sizable demand in the market.
The report on the hyperparathyroidism market covers the following areas:
- Hyperparathyroidism Market sizing
- Hyperparathyroidism Market forecast
- Hyperparathyroidism Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hyperparathyroidism market vendors that include AbbVie Inc., Accord Healthcare Ltd., AdvaCare Pharma, Alkem Laboratories Ltd., Amgen Inc., Ascendis Pharma AS, Aurobindo Pharma Ltd., Biocon Ltd., Cipla Inc., Dr Reddys Laboratories Ltd., EA Pharma Co. Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Lupin Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the hyperparathyroidism market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.